Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atomoxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 11/20 | 0.78 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.78 |
| ▸ | TSHR | P16473 | 3/20 | 0.78 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.78 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.78 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.78 |
| ▸ | HTR2A | P28223 | 2/20 | 0.78 |
| ▸ | HTR2C | P28335 | 2/20 | 0.78 |
| ▸ | HRH1 | P35367 | 2/20 | 0.78 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.78 |
| ▸ | DRD3 | P35462 | 2/20 | 0.78 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.78 |
| ▸ | HTR2B | P41595 | 2/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.78 |
| ▸ | KLF10 | Q13118 | 2/20 | 0.78 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atomoxetine SCHEMBL4943829 | 1.00 | SLC6A4 (0.78) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Atomoxetine SCHEMBL10523421 | 1.00 | SLC6A4 (0.78) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Atomoxetine SCHEMBL5011175 | 0.90 | SLC6A4 (0.86) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Atomoxetine SCHEMBL4730875 | 0.90 | SLC6A4 (0.86) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Atomoxetine SCHEMBL4082557 | 0.90 | SLC6A4 (0.86) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Atomoxetine SCHEMBL12047445 | 0.88 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Atomoxetine SCHEMBL341802 | 0.88 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Atomoxetine SCHEMBL5783906 | 0.88 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Atomoxetine SCHEMBL29440242 | 0.88 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Atomoxetine SCHEMBL2209541 | 0.88 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110294680-A | A kind of preparation method in levels Moses spit of fland | 北京深蓝海生物医药科技有限公司 | 2019-10-01 | — | — | CN | claimed |
| CN-110051657-A | The purposes of mandelic acid | 上海市计划生育科学研究所 | 2019-07-26 | — | — | CN | claimed |
| CN-104434890-A | Application of mandelic acid | SHANGHAI INST PLANNED PARENTHOOD RES | 2015-03-25 | — | — | CN | claimed |
| CN-110194719-B | Preparation method of R- (-) -atomoxetine hydrochloride | 山东大学 | 2020-05-15 | — | — | CN | disclosed |
| CN-110294680-A | A kind of preparation method in levels Moses spit of fland | 北京深蓝海生物医药科技有限公司 | 2019-10-01 | — | — | CN | disclosed |
| CN-110194719-A | A kind of preparation method in R- (-)-levels Moses spit of fland | 山东大学 | 2019-09-03 | — | — | CN | disclosed |
| CN-110051657-A | The purposes of mandelic acid | 上海市计划生育科学研究所 | 2019-07-26 | — | — | CN | disclosed |
| CN-104434890-A | Application of mandelic acid | SHANGHAI INST PLANNED PARENTHOOD RES | 2015-03-25 | — | — | CN | disclosed |
| US-7439398-B2 | Enantiomerically pure atomoxetine and tomoxetine mandelate | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2008-10-21 | — | — | US | disclosed |
| US-7439398-B2 | Enantiomerically pure atomoxetine and tomoxetine mandelate | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2008-10-21 | — | — | US | disclosed |
| WO-2008062473-A1 | PROCESS FOR PREPARING ATOMOXETINE HYDROCHLORIDE | CADILA HEALTHCARE LIMITED (IN) | 2008-05-29 | — | — | WO | disclosed |
| EP-1682485-A2 | ENANTIOMERICALLY PURE ATOMOXETINE AND TOMOXETINE MANDELATE | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2006-07-26 | — | — | EP | disclosed |
| EP-1682485-A2 | ENANTIOMERICALLY PURE ATOMOXETINE AND TOMOXETINE MANDELATE | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2006-07-26 | — | — | EP | disclosed |
| WO-2006004923-A3 | ENANTIOMERICALLY PURE ATOMOXETINE AND TOMOXETINE MANDELATE | TEVA PHARM FINE CHEMICALS SRL (IT) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006037055-A1 | SYNTHESIS OF ATOMOXETINE HYDROCHLORIDE | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-06 | — | — | WO | disclosed |
| WO-2006009884-A1 | 3-ARYLOXY-3-ARYLPROPYLAMINE SYNTHESIS | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006004923-A2 | ENANTIOMERICALLY PURE ATOMOXETINE AND TOMOXETINE MANDELATE | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006004923-A2 | ENANTIOMERICALLY PURE ATOMOXETINE AND TOMOXETINE MANDELATE | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2006-01-12 | — | — | WO | disclosed |
| US-20060009490-A1 | Enantiomerically pure atomoxetine and tomoxetine mandelate | TEVA PHARMACEUTICALS USA, INC. | 2006-01-12 | — | — | US | disclosed |
| US-20060009490-A1 | Enantiomerically pure atomoxetine and tomoxetine mandelate | TEVA PHARMACEUTICALS USA, INC. | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009490-A1 | Enantiomerically pure atomoxetine and tomoxetine mandelate | SLC6A4, HTR5A, SLC6A2 | SLC6A2 3/4885SLC6A4 1/4885CYP2D6 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.